The Therapeutic Potential of 4-1BB (CD137) in Cancer
Abstract
Techniques for modulating immune cells for cancer therapy have been widely studied. One key approach that is being clinically tested is developing tumor-destructive cell-mediated immune responses by regulating co-stimulatory molecules. 4-1BB (CD137), a member of the TNF receptor family, is expressed following activation of T and NK cells. Recently, it has been reported that DCs also express 4-1BB. Cross-linking of 4-1BB provides a potent co-stimulatory signal for lymphocytes via signal transduction pathways that modulate a number of cellular responses. One remarkable response is stimulation of anti-tumor activity in vivo and in vitro. We here review the potential role of 4-1BB in cancer immunotherapy focusing on the cellular and molecular mechanisms involved.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
d-Serine crosses the blood-brain barrier by amino acid transporter solute carrier family 6 member 14.
“d-Serine serves as a neuromodulator and crosses the BBB by amino acid transporter solute carrier family 6 member 14 (refs. 31–35).”
From Blood–brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system (2025) · cites this paper as [35]
Cites
Still being checked.
Cited by
Sorted by citations
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,074 · see citing works
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
Löb, S., Königsrainer, A., Rammensee, H., Opelz, G., & Terness, P. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2639 · Cited by 421 · see citing works
Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)
O'Day, S. J., Hamid, O., & Urba, W. J. (2007) · Cancer · doi:10.1002/cncr.23086 · Cited by 309 · see citing works
Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation
Munn, D. H. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.01.002 · Cited by 176 · see citing works
Blood–brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system
Wang, C., Xue, Y., Markovic, T., Li, H., Wang, S., Zhong, Y., Du, S., Zhang, Y., Hou, X., Yu, Y., et al. (2025) · Nature Materials · doi:10.1038/s41563-024-02114-5 · Cited by 171 · see citing works
Borghaei, H., Smith, M. R., & Campbell, K. S. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.09.067 · Cited by 128 · see citing works
Murillo, O., Arina, A., Hervás‐Stubbs, S., Gupta, A., McCluskey, B., Dubrot, J., Palazón, A., Azpilikueta, A., Ochoa, M. C., Alfaro, C., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0285 · Cited by 84 · see citing works
CD137 on inflamed lymphatic endothelial cells enhances CCL21‐guided migration of dendritic cells
Teijeira, Á., Palazón, A., Garasa, S., Marré, D., Aubá, C., Rogel, A., Murillo, O., Martínez‐Forero, I., Lang, F., Melero, I., et al. (2012) · The FASEB Journal · doi:10.1096/fj.11-201061 · Cited by 53 · see citing works
Ou, X., Cai, S., Liu, P., Zeng, J., He, Y., Wu, X., & Du, J. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0315-9 · Cited by 49 · see citing works
D, S. M. M., & Nitti, D. (2007) · Medicinal Research Reviews · doi:10.1002/med.20110 · Cited by 44 · see citing works
Luo, Q., Yang, B., Tao, W., Li, J., Kou, L., Lian, H., Che, X., He, Z., & Sun, J. (2016) · Biomaterials Science · doi:10.1039/c6bm00788k · Cited by 43 · see citing works
Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
Li, S., & Liu, Y. (2013) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s46199 · Cited by 42 · see citing works
Dubrot, J., Palazón, A., Alfaro, C., Azpilikueta, A., Ochoa, M. C., Rouzaut, A., Martínez‐Forero, I., Teijeira, Á., Berraondo, P., Bon, A. L., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25333 · Cited by 42 · see citing works
Pasero, C., Barbarat, B., Just‐Landi, S., Bernard, A., Aurran, T., Rey, J., Eldering, E., Truneh, A., Costello, R. T., & Olive, D. (2009) · European Journal of Immunology · doi:10.1002/eji.200939069 · Cited by 39 · see citing works
A dual role of p21waf1/cip1 gene in apoptosis of HEp-2 treated with cisplatin or methotrexate
Pavelić, S. K., Čaćev, T., & Kralj, M. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.28 · Cited by 24 · see citing works
Eckstrum, K. S., & Bany, B. M. (2011) · Cell and Tissue Research · doi:10.1007/s00441-011-1171-0 · Cited by 18 · see citing works
Gong, W., Ming-chun, J., Cao, Z., Wang, L., Qian, Y., Hu, M., Li, Q., & Pan, X. (2008) · Cellular and Molecular Immunology · doi:10.1038/cmi.2008.6 · Cited by 14 · see citing works
Immune response-associated gene profiling in Japanese melanoma patients using multi-omics analysis
Akiyama, Y., Kiyohara, Y., Yoshikawa, S., Otsuka, M., Kondou, R., Nonomura, C., Miyata, H., Iizuka, A., Ashizawa, T., Ohshima, K., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.6173 · Cited by 4 · see citing works
Radiation Immune Modulation Therapy of Glioma
Bertil, R. R. (2011) · InTech eBooks · doi:10.5772/22560 · Cited by 1 · see citing works
Schreiber, T. H. (2016) · Springer eBooks · doi:10.1007/978-3-319-29827-6_3 · Cited by 1 · see citing works
Jiang, D.-C., Zhou, D. X., Xu, X.-R., Jiang, X.-L., Yin, L.-S., Zhong, C.-Y., & Miao, Q. (2026) · Antibody Therapeutics · doi:10.1093/abt/tbag014
- Authors
- Nam, K.-O., Kang, W., Kwon, B., Kim, S., & Lee, H.-W.
- Affiliations
- Kyung Hee University (KR)
- Venue
- Current Cancer Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2005-08-01
- Volume
- 5
- Issue
- 5
- Pages
- 357-363
- ISSN
- 1568-0096 (ISSN-L)
- OpenAlex
- W2106302477
- Cited by
- 21
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2017: 1 · 2016: 2 · 2013: 1 · 2012: 1
- FWCI
- 0.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Cancer Drug Targets (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- 4-1BB, cancer immunotherapy, costimulatory molecules, TNF receptor superfamily, dendritic cells, T cells, natural killer cells, cell-mediated immunity, anticancer activity, signal transduction
- MeSH terms
- Animals, Antibodies, Monoclonal, Antineoplastic Agents, Humans, Immunotherapy, Lymphocyte Activation, Neoplasms, Signal Transduction, Antigens, CD, T-Lymphocyte Subsets, Receptors, Nerve Growth Factor, Receptors, Tumor Necrosis Factor, CD8-Positive T-Lymphocytes, Tumor Necrosis Factor Receptor Superfamily, Member 9
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
